AzTrials
AzTrials

Coronary Artery DiseaseNCT03227588

Evaluation of the Opsens Fractional Flow Reserve (FFR) Wire as a "Work Horse" Wire

An observational study of Coronary Artery Disease, run by Central Arkansas Veterans Healthcare System at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The use of fractional flow reserve (FFR) has improved outcomes in percutaneous coronary interventions (PCI) in patients with symptomatic stable coronary artery disease (CAD) with intermediate angiographic stenoses. Read more about this study

Who is it for?
Ages 18 to 89 years
Conditions the study is for
Coronary Artery Disease
What is being tested?
Fractional Flow Reserve
How many people
1,000 participants
Where
1 siteUnited States
Study dates
10 Apr 2017to 10 Dec 2019
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 89 years
  • All sexes
  • Adult, Older adult

Study population: Patients (age 18-89 years old) eligible and in whom the operator has performed FFR will be included to systematically evaluate the performance of the OptoWire FFR wire. A total of 1000 consecutive patients deemed to require FFR as part of clinical care will be included. It is felt that 1000 patients represent a reasonable sample size to study the OptoWire FFR wire handling characteristics, the primary endpoint of the study.

Who may be able to join

  • Patients (age 18-89 years old) eligible and in whom the operator has performed FFR will be included to systematically evaluate the performance of the OptoWire FFR wire. A total of 1000 consecutive patients deemed to require FFR as part of clinical care will be included. It is felt that 1000 patients represent a reasonable sample size to study the OptoWire FFR wire handling characteristics, the primary endpoint of the study

Who cannot join

  • Not a candidate for FFR
  • Chronic total occlusion lesion
  • Hemodynamically unstable
  • Saphenous vein graft lesions -

Trial locations and contacts

1 site in 1 country.

Barry F. Uretsky, MD contact

501-257-1000

barry.uretsky@va.gov

Kristin G Miller, RN, CCRC contact

501-257-5893

kristin.miller4@va.gov

United States1 site, 1 recruiting
  • John L. McClellan Memorial Veterans Hospital

    Little Rock, Arkansas, 72205

    Kristin Miller, RN, 501-257-5893, kristin.miller4@va.gov

    Barry F Uretsky, MD

    Recruiting

Other trials in United States

About this study

The use of fractional flow reserve (FFR) has improved outcomes in percutaneous coronary interventions (PCI) in patients with symptomatic stable coronary artery disease (CAD) with intermediate angiographic stenoses. It is a clinical tool used routinely in cardiac catheterization laboratories throughout the world including the Little Rock VA Hospital. The technique utilizes a pressure transducer constructed as part of an 0.014" guidewire. An FFR of >0.80 has been linked with myocardial ischemia found with nuclear stress and dobutamine echo stress testing. The FAME trial clearly demonstrated its value in improving long-term outcomes as compared to use of angiography alone. As such, the use of FFR is incorporated into both AHA ACC and European PCI guideline recommendations as part of routine care for intermediate lesions. A "work horse" guide wire is so defined because it can be used in most PCI cases. It combines a low tip load (to avoid intimal dissection, with excellent (ideally, one to one) torque transmission and trackability through tortuous lesions. Recently the FDA has approved an FFR guide wire, OptoWire, (Opsens, Quebec City, Quebec, CAN) which uses light transmission to measure pressure rather than electrical transduction wires. The primary purpose of the present study is to determine how effective this wire is as a work horse wire in patients in whom FFR is required. The OptoWire may also have the advantage of less "drift" occurring during the procedure. Drift refers to the change in pressure due to issues related to the wire and measuring system, rather than a true change in pressure. All current FFR wire systems demonstrate some degree of drift requiring measuring pressure of the wire in the aorta after the procedure is completed to determine if, and to what extent, drift has occurred. Thus, a secondary aim of this study will determine the degree of drift.

Read the detailed description

EVALUATION OF THE OPSENS FRACTIONAL FLOW RESERVE (FFR) WIRE AS A "WORK HORSE" WIRE

INVESTIGATORS:

PRINCIPAL INVESTIGATOR: BARRY F URETSKY, MD CO-INVESTIGATOR: ABDUL HAKEEM, MD CO-INVESTIGATOR: MALEK AL-HAWWAS, MD

Introduction The use of fractional flow reserve (FFR) has improved outcomes in percutaneous coronary interventions (PCI) in patients with symptomatic stable coronary artery disease (CAD) with intermediate angiographic stenoses. It is a clinical tool used routinely in cardiac catheterization laboratories throughout the world including the Little Rock VA hospital. The technique utilizes a pressure transducer constructed as part of an 0.014" guidewire. The wire is passed distal to the stenosis. Under the condition of maximal hyperemia induced by a drug, typically adenosine, the pressure proximal to the stenosis, i.e. aortic pressure or Pa and the pressure distal to the stenosis, Pd, are measured. The ratio, Pd/Pa, under maximal flow or hyperemia is known as the fractional flow reserve (FFR). An FFR of <0.80 has been correlated with observed myocardial ischemia using other diagnostic methods, particularly nuclear stress and dobutamine echo stress testing. The FAME trial clearly demonstrated its value in improving long-term outcomes as compared to use of angiography alone (1). As such, the use of FFR is incorporated into both AHA ACC and European PCI guideline recommendations as part of routine care for intermediate lesions (2,3).

One of the limitations of the use of the FFR pressure wire itself is that its handling characteristics are somewhat inferior to a standard "work horse" guide wire used for PCI. A "work horse" guide wire is so defined because it can be used in most PCI cases. It combines a low tip load (to avoid intimal dissection) with excellent (ideally, one-to-one) torque transmission and trackability through tortuous lesions. There are several different work horse wires available. Although the wires may be different for different Cath Labs and operators, the wires are universally used to maximize safety, efficacy, and efficiency of PCI.

In patients specifically requiring FFR to determine the value of PCI, it would be ideal if an FFR wire was as effective as a work horse wire so it could be used in difficult-to-traverse lesions. However, due to the complex electronics within current FFR wires, handling characteristics of previously used wires are inferior to current work horse wires. Recently the FDA has approved an FFR guide wire, OptoWire, (Opsens, Quebec City, Quebec, CAN) using light transmission to measure pressure rather than electrical transduction (4). It is commercially available in the United States. Its handling characteristics appear to approach that of a work horse guide wire and may represent an improvement over electrical transduction wires. The primary purpose of the present study is to determine how effective this wire is as a work horse wire in patients in whom FFR is required.

The OptoWire may also have the advantage of less "drift" occuring during the procedure. Drift refers to the change in pressure due to issues related to the wire and measuring system, rather than a true change in pressure. All current FFR wire systems demonstrate some degree of drift requiring measuring pressure of the wire in the aorta after the procedure is completed to determine if, and to what extent, drift has occurred. Thus, a secondary aim of this study will determine the degree of drift.

In clinical practice, FFR is performed before, and often after, PCI. In a study of 574 patients treated at the Little Rock VA (IRB Study, #779601), teh investigators found that approximately 20% of angiographically optimized PCI still had an ischemic FFR. The investigators further found that this ischemic value could be improved by further treatments including balloon angioplasty and stenting. Thus, the secondary purpose is to measure FFR after successful PCI to ascertain the incidence of persistently ischemic FFR after optimized angiographic stenting to confirm the result from out previous study.

Statistical analysis

This study is descriptive. It will use means and standard deviation for continuous variables and prevalence or incidence in percentages as appropriate to show results. As there is no comparator group, comparative statistics will not be employed.

Research aspect of study

The research aspect of the study is limited to the systematic collection and analysis of data using the Opsens FFR wire with plan for publication. The other aspects of the study are considered part of routine clinical care. They include passage of FFR wire, measurement of FFR pre- and post-PCI, and performance of PCI itself.

Significance of study

A wire that can be used as a workhorse as well as be able to measure FFR would be of great value. The more effective and efficient is the FFR wire in not only measuring pre-PCI FFR but being able to be used for PCI and be stable and durable enough to be used for post-PCI optimization, the greater is the probability that this approach will be more generally adopted into clinical practice. Demonstration that the Opsens FFR wire is effective in this regard should further this goal.

The investigators previously demonstrated that 21% or about 1 in 5 patients had an ischemic FFR after satisfactory angiographic result. This study will confirm previous results or suggest either an over- or under-estimation of that incidence.

Being tested
Fractional Flow Reserve
Keywords
Fractional Flow Reserve, Percutaneous Coronary Intervention
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fractional Flow ReserveDiagnostic test

    This is a prospective data collection study for patients that have undergone FFR.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Opsens FFR Wire Performance

    Satisfactory performance is defined as the ability to perform the entire PCI plus measure FFR pre and post PCI with drift <0.05.

    Measured: Acute result at end of procedure

Secondary outcomes (1)
  1. Incidence of Ischemic or Low Non-ischemic FFR post PCI requiring further intervention

    Measured: Acute result at end of procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2017
  2. Study start10 Apr 2017
  3. Primary completion10 Dec 2019 (estimated)
  4. Study completion10 Dec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT03227588
Sponsor's protocol ID
966635
Status last verified
Feb 2019
First submitted
27 Jun 2017
Last updated
12 Feb 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.

    PubMed 19144937
  • Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res. 2015 Jun;8(4):211-20. doi: 10.1007/s12265-015-9632-6. Epub 2015 May 19.

    PubMed 25986910
  • Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122. doi: 10.1016/j.jacc.2011.08.007. Epub 2011 Nov 7. No abstract available.

    PubMed 22070834
  • Agarwal SK, Kasula S, Hacioglu Y, Ahmed Z, Uretsky BF, Hakeem A. Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes. JACC Cardiovasc Interv. 2016 May 23;9(10):1022-31. doi: 10.1016/j.jcin.2016.01.046.

    PubMed 27198682
  • Uretsky BF, Agarwal SK, Vallurupalli S, Al-Hawwas M, Hasan R, Miller K, Hakeem A. Prospective Evaluation of the Strategy of Functionally Optimized Coronary Intervention. J Am Heart Assoc. 2020 Feb 4;9(3):e015073. doi: 10.1161/JAHA.119.015073. Epub 2020 Jan 30.

    PubMed 32013707

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease, run by Central Arkansas Veterans Healthcare System at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Barry F. Uretsky, MD (501-257-1000, barry.uretsky@va.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Opsens FFR Wire Performance (time frame: Acute result at end of procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03227588, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in